Meda AB

From Wikipedia, the free encyclopedia

MEDA AB is a Swedish pharmaceutical company that focuses on "marketing and market-adapted product development". Through their purchase of Medpointe, they own the pharmaceutical products of Carter-Wallace, now marketed under the name Wallace Pharmaceuticals.[1][2]

In 2008 the company bought branches in Western and Eastern Europe from Valeant Pharmaceuticals for $392 Million. [3]

References

  1. ↑ "Carter-Wallace". Encyclopedia of New Jersey. Retrieved 2011-09-26. "Wallace Pharmaceuticals became MedPointe's prescription pharmaceuticals division. ..." 
  2. ↑ "About Us". Wallace Pharmaceuticals. Retrieved 2011-09-26. "September 2001 brought the biggest change to the Carter-Wallace business in more than one-hundred years when the pharmaceutical and diagnostics businesses of Carter-Wallace, Inc. was sold to MedPointe Capital Partners, backed by private equity firms The Carlyle Group and The Cypress Group in a cash deal valued at approximately $408 million. In the deal, MedPointe acquired Wallace Laboratories, Carter-Wallace's pharmaceutical arm, and Wampole Laboratories, its diagnostics unit, as well as the rights to the Carter-Wallace name." 
  3. ↑ http://www.biospace.com/news_story.aspx?NewsEntityId=105546
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.